A Phase 2 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-24.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 19th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 2, and was the 3rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 19th largest by enrollment, is one of 6 that started in 2011, is one of 6 in phase 2, and was the 7th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
The duration of study participation depended on the status of the participant at screening:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion criteria:
LDL-C \< 100 mg/dL (\< 2.59 mmol/L):
OR
Laboratory findings measured before randomization:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
Drug: Placebo (for alirocumab) · Drug: Atorvastatin
Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Placebo (for alirocumab) · Drug: Atorvastatin
Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Placebo (for alirocumab) · Drug: Atorvastatin
Two SC injections in the abdomen only.
Also known as: SAR236553, REGN727
Two subcutaneous (SC) injections in the abdomen only.
Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first study drug injection up to 21 days after last study drug injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
Time frame: Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
Time frame: Week 12 (LOCF)
Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).
Time frame: Baseline to Week 12 (LOCF)
Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis
Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
The study was conducted at 38 centers in the United States of America. Overall, 514 participants were screened between January 2011 and August 2011, 331 of whom were screen failures and screen failures were mainly due to exclusion criteria met.
| Milestone | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Started | 31 | 30 | 31 | 31 | 30 | 30 |
| Treated | 31 | 30 | 31 | 31 | 29 | 30 |
| Completed | 31 | 29 | 30 | 27 | 23 | 25 |
| Not completed | 0 | 1 | 1 | 4 | 7 | 5 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 3 | 1 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant moved | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Consent withdrawn by participant | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug auto-injector administration | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other than above | 0 | 0 | 0 | 2 | 1 | 0 |
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first study drug injection up to 21 days after last study drug injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | -5.1 ± 3.1 | -39.6 ± 3.2 | -64.2 ± 3.1 | -72.4 ± 3.2 | -43.2 ± 3.3 | -47.7 ± 3.2 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mmol/L | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis | -0.20 ± 0.10 | -1.37 ± 0.10 | -2.10 ± 0.10 | -2.38 ± 0.10 | -1.46 ± 0.11 | -1.62 ± 0.10 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis | -7.6 ± 3.9 | -53.0 ± 4.0 | -81.2 ± 3.9 | -92.0 ± 4.0 | -56.4 ± 4.1 | -62.5 ± 4.0 |
| percentage of participants | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| LDL-C <100 mg/dL (2.59 mmol/L) | 16.1 | 93.3 | 96.8 | 100.0 | 89.3 | 96.7 |
| LDL-C <70 mg/dL (1.81 mmol/L) | 3.2 | 46.7 | 83.9 | 100.0 | 46.4 | 56.7 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Total Cholesterol (n= 31, 30, 31, 29, 28, 30) | -1.6 ± 2.3 | -23.0 ± 2.3 | -39.7 ± 2.3 | -45.2 ± 2.3 | -28.0 ± 2.4 | -29.8 ± 2.3 |
| HDL-C (n= 31, 30, 31, 29, 28, 30) | -1.0 ± 2.3 | 6.7 ± 2.4 | 4.1 ± 2.3 | 5.5 ± 2.4 | 6.3 ± 2.5 | 8.5 ± 2.4 |
| Non-HDL-C (n= 31, 30, 31, 29, 28, 30) | -2.2 ± 2.9 | -33.6 ± 2.9 | -55.6 ± 2.9 | -62.5 ± 3.0 | -37.4 ± 3.0 | -40.7 ± 2.9 |
| Apo-B (n= 30, 30, 30, 29, 27, 30) | 2.2 ± 2.9 | -27.3 ± 2.9 | -48.1 ± 2.9 | -56.1 ± 2.9 | -28.7 ± 3.1 | -33.1 ± 2.9 |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Fasting Triglycerides (n= 31, 30, 31, 29, 28, 30) | 9.7 (-15 to 30.7) | -6.6 (-17.7 to 7.1) | -5.5 (-22.1 to 10.7) | -18.9 (-31.7 to -6.1) | -10.8 (-25.4 to 13.3) | -8.4 (-21.5 to 10.1) |
| Lipoprotein(a) (n= 30, 30, 30, 29, 27, 30) | 0.0 (-11.8 to 11.5) | -13.3 (-33.3 to 0.0) | -26.1 (-36.7 to -8.0) | -28.6 (-46.9 to -22.2) | -16.7 (-33.3 to -6.3) | -7.9 (-18.8 to 0.0) |
Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.
| ratio | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis | 0.05 ± 0.03 | -0.23 ± 0.03 | -0.35 ± 0.03 | -0.42 ± 0.03 | -0.23 ± 0.03 | -0.29 ± 0.03 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/31 (3.2%) | 10/31 (32.3%) |
| Alirocumab 50 mg Q2W | — | 0/30 (0%) | 14/30 (46.7%) |
| Alirocumab 100 mg Q2W | — | 1/31 (3.2%) | 14/31 (45.2%) |
| Alirocumab 150 mg Q2W | — | 0/31 (0%) | 12/31 (38.7%) |
| Alirocumab 200 mg Q4W | — | 1/31 (3.2%) | 12/31 (38.7%) |
| Alirocumab 300 mg Q4W | — | 1/28 (3.6%) | 10/28 (35.7%) |
| Event | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders | 0/31 | 0/30 | 0/31 | 0/31 | 0/31 | 1/28 |
| Humerus fractureInjury, poisoning and procedural complications | 0/31 | 0/30 | 0/31 | 0/31 | 0/31 | 1/28 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/31 | 0/30 | 1/31 | 0/31 | 0/31 | 0/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/31 | 0/30 | 0/31 | 0/31 | 1/31 | 0/28 |
| Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders | 1/31 | 0/30 | 0/31 | 0/31 | 0/31 | 0/28 |
| Event | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/31 | 4/30 | 3/31 | 0/31 | 1/31 | 1/28 |
| SinusitisInfections and infestations | 3/31 | 0/30 | 1/31 | 2/31 | 1/31 | 0/28 |
| Injection site erythemaGeneral disorders | 0/31 | 0/30 | 3/31 | 3/31 | 1/31 | 1/28 |
| Injection site pruritusGeneral disorders | 0/31 | 0/30 | 2/31 | 3/31 | 1/31 | 0/28 |
| Urinary tract infectionInfections and infestations | 0/31 | 1/30 | 0/31 | 0/31 | 0/31 | 2/28 |
| AnaemiaBlood and lymphatic system disorders | 0/31 | 1/30 | 0/31 | 0/31 | 0/31 | 2/28 |
| DiarrhoeaGastrointestinal disorders | 0/31 | 0/30 | 1/31 | 1/31 | 1/31 | 2/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/31 | 0/30 | 1/31 | 1/31 | 0/31 | 2/28 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/31 | 0/30 | 0/31 | 0/31 | 2/31 | 2/28 |
| FallInjury, poisoning and procedural complications | 0/31 | 0/30 | 0/31 | 1/31 | 1/31 | 2/28 |
Randomized population.
| Age, Continuous(years) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.3 ± 8.5 | 58.5 ± 9.1 | 58.1 ± 9.2 | 59.9 ± 11.1 | 54.9 ± 10.8 | 55.5 ± 10.1 | 56.7 ± 10.0 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 13 | 18 | 21 | 13 | 16 | 96 |
| Male | 16 | 17 | 13 | 10 | 17 | 14 | 87 |
| Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L(mmol/L) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 3.4 ± 0.7 | 3.2 ± 0.7 | 3.3 ± 0.8 | 3.2 ± 0.7 | 3.3 ± 0.5 | 3.4 ± 0.6 | 3.3 ± 0.7 |
| LDL-C in mg/dL(mg/dL) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 100 mg Q2W | Alirocumab 150 mg Q2W | Alirocumab 200 mg Q4W | Alirocumab 300 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 130.2 ± 27.3 | 123.2 ± 27.9 | 127.0 ± 30.4 | 124.7 ± 26.9 | 127.2 ± 19.6 | 131.6 ± 24.8 | 127.3 ± 26.2 |
The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 3 years 9 months after primary completion. A results delay was requested in Dec 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab